ArticleNeurology2025
Patterns of Longitudinal Regional Brain Atrophy in Patients With Different Progressive Supranuclear Palsy Clinical Variants.
Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pallidal Volumetry and Neutrophil-to-Lymphocyte Ratio in Differentiating Progressive Supranuclear Palsy from Parkinson's Disease.Diseases (Basel, Switzerland) · 2026Article
- Associations Between Nonspecific Blood-Derived Inflammatory Indices and MRI-Derived Frontal Network Degeneration in Progressive Supranuclear Palsy.Neurology international · 2026Article
- Automated Volumetric Assessment of the Pallidum and Ventral Diencephalon for Differentiating Progressive Supranuclear Palsy from Parkinson's Disease.Diseases (Basel, Switzerland) · 2026Article
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- Magnetic resonance imaging volumetry in atypical parkinsonism: current evidence and neuroradiological perspectives.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectivesProgressive supranuclear palsy (PSP) is characterized by progressive atrophy of brainstem, subcortical, and frontal regions. It is unknown whether longitudinal atrophy patterns differ between PSP-Richardson syndrome (PSP-RS) and cortical and subcortical clinical variants of PSP and whether atrophy rates could be useful outcome measures for treatment trials. We aimed to determine whether regional rates of atrophy differ across PSP clinical variants and determine sample size estimates for clinical treatment trials.
methodsWe identified participants with PSP-RS, PSP-cortical, or PSP-subcortical variants recruited by the Neurodegenerative Research Group who underwent 2 annual 3T MRI scans. Volumes were calculated for 10 regions of interest, and mixed-effects regression analysis was performed to compare annualized rates of atrophy across groups, accounting for confounders. Sample sizes required to power placebo-controlled treatment trials to detect a 20% treatment effect with 80% power were calculated for rates of atrophy and clinical metrics, including the PSP Rating Scale.
resultsFifty patients with PSP-RS (baseline age = 69 [interquartile range 64 to 75], 46% female), 18 with PSP-cortical (74 [70 to 76], 50% female), 20 with PSP-subcortical (71 [67 to 77], 60% female), and 32 controls (69 [66 to 72], 72% female) were included. Rates of midbrain, cerebellar dentate, and subthalamic atrophy were greater in all PSP variants than in controls. The PSP-RS group showed greater midbrain atrophy rates than PSP-subcortical (-1.6% difference [95% CI -2.4 to -0.7], DISCUSSION: Regional patterns of brain atrophy differ across PSP clinical variants, although midbrain atrophy was common in all variants. Sample size estimates suggest that combining the PSP Rating Scale and targeted MRI volumes provides the optimum outcome measure for clinical treatment trials recruiting patients with PSP clinical variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.